Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates generic emtricitabine(FTC) plus adefovir dipivoxil in Chinese naive HBV
related cirrhosis patients. Patients were divided into 2 groups: compensated HBV related
cirrhosis patients and decompensated HBV related cirrhosis patients.
Phase:
Phase 4
Details
Lead Sponsor:
Asian-Pacific Alliance of Liver Disease, Beijing
Collaborators:
Beijing Ditan Hospital Hebei Medical University Pharmaceutical Factory National Health and Family Planning Commission, P.R.China